| ATC code |
ATC level name |
| A03AX15 |
menthae piperitae aetheroleum |
| A05BA09 |
metadoxine |
| A06AX08 |
tenapanor |
| A10BD26 |
metformin and lobeglitazone |
| A10BG04 |
lobeglitazone |
| A10BH08 |
teneligliptin |
| A10BJ07 |
beinaglutide |
| A10BK07 |
luseogliflozin |
| A16AX16 |
givosiran |
| A16AX17 |
triheptanoin |
| A16AX18 |
lumasiran |
| A16AX30 |
sodium benzoate and sodidum phenylacetate |
| B03AD05 |
ferrous gluconate |
| B05XA18 |
zinc sulfate |
| B06AX02 |
betibeglogene autotemcel |
| C01DX22 |
vericiguat |
| C09BX05 |
ramipril and bisoprolol |
| C10AX16 |
inclisiran |
| C10BA10 |
bempedoic acid and ezetimibe |
| C10BX18 |
atorvastatin, amlodipine and ramipril |
| D01BA03 |
fosravuconazole |
| D05AX55 |
tazarotene and ulobetasol |
| D06BX03 |
tirbanibulin |
| D10AF07 |
minocycline |
| D11AH07 |
tralokinumab |
| D11AX26 |
caffeine |
| G02CX05 |
bremelanotide |
| G03AA18 |
drospirenone and estetrol |
| H01AC07 |
somapacitan |
| H01CC54 |
relugolix, estradiol and norethisterone |
| H02CA03 |
ketoconazole |
| H05AA04 |
abaloparatide |
| H05BX05 |
calcifediol |
| J01DH56 |
imipenem, cilastatin and relebactam |
| J01DI04 |
cefiderocol |
| J01MA24 |
levonadifloxacin |
| J01MA25 |
lascufloxacin |
| J04AK08 |
pretomanid |
| J05AJ04 |
cabotegravir |
| J05AX28 |
bulevirtide |
| J05AX29 |
fostemsavir |
| J07BB04 |
influenza, virus like particles
|
| J07BX02 |
ebola vaccines |
| L01EE04 |
selumetinib |
| L01EH03 |
tucatinib |
| L01EL03 |
zanubrutinib |
| L01EM04 |
duvelisib |
| L01EX15 |
pexidartinib |
| L01EX16 |
erdafitinib |
| L01EX17 |
capmatinib |
| L01EX18 |
avapritinib |
| L01EX19 |
ripretinib |
| L01EX20 |
pemigatinib |
| L01EX21 |
tepotinib |
| L01XC34 |
moxetumomab pasudotox |
| L01XC35 |
tafasitamab |
| L01XC36 |
enfortumab vedotin |
| L01XC37 |
polatuzumab vedotin |
| L01XC38 |
isatuximab |
| L01XC39 |
belantamab mafodotin |
| L01XC40 |
dostarlimab |
| L01XC41 |
trastuzumab deruxtecan |
| L01XK05 |
veliparib |
| L01XX69 |
lurbinectedin |
| L01XX70 |
axicabtagene ciloleucel |
| L01XX71 |
tisagenlecleucel |
| L01XY02 |
pertuzumab and trastuzumab |
| L04AA45 |
filgotinib |
| L04AA46 |
itacitinib |
| L04AA47 |
inebilizumab |
| L04AC19 |
satralizumab |
| M02AA29 |
esflurbiprofen |
| M09AX08 |
golodirsen |
| M09AX09 |
onasemnogene abeparvovec |
| M09AX10 |
risdiplam |
| M09AX11 |
palovarotene |
| N01BB59 |
bupivacaine and meloxicam |
| N02AA11 |
oxymorphone |
| N02BG11 |
mirogabalin |
| N03AX25 |
cenobamate |
| N03AX26 |
fenfluramine |
| N04CX01 |
istradefyllin |
| N05CD15 |
nimetazepam |
| R01AD59 |
mometasone, combinations |
| R07AX32 |
ivacaftor, tezacaftor and elexacaftor |
| S01GA07 |
brimonidine |
| S01LA07 |
abicipar pegol |
| ATC code |
New name/new ATC 4th level |
| J05AJ |
Integrase inhibitors
|
| L01CE |
Topoisomerase 1 (TOP1) inhibitors |
| L01E |
PROTEIN KINASE INHIBITORS |
| L01EA |
BCR-ABL tyrosine kinase inhibitors |
| L01EB |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors |
| L01EC |
B-Raf serine-threonine kinase (BRAF) inhibitors |
| L01ED |
Anaplastic lymphoma kinase (ALK) inhibitors |
| L01EE |
Mitogen-activated protein kinase (MEK) inhibitors |
| L01EF |
Cyclin-dependent kinase (CDK) inhibitors |
| L01EG |
Mammalian target of rapamycin (mTOR) kinase inhibitors |
| L01EH |
Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors |
| L01EJ |
Janus-associated kinase (JAK) inhibitors |
| L01EK |
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors |
| L01EL |
Bruton's tyrosine kinase (BTK) inhibitors |
| L01EM |
Phosphatidylinositol-3-kinase (Pi3K) inhibitors |
| L01EX |
Other protein kinase inhibitors |
| L01XF |
Retinoids for cancer treatment |
| L01XG |
Proteasome inhibitors |
| L01XH |
Histone deacetylase (HDAC) inhibitors |
| L01XJ |
Hedgehog pathway inhibitors |
| L01XK |
Poly (ADP-ribose) polymerase (PARP) inhibitors |
| N04C |
OTHER ANTIPARKINSON DRUGS |
| N04CX |
Other antiparkinson drugs |
